Current and future options in cholesterol lowering treatments.

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Cardiovascular events are significantly influenced by LDL-C levels.
• Therapeutic strategies for LDL-C reduction have advanced, improving atherosclerotic process and clinical outcomes.
• Effective management of lipid levels is crucial for cardiovascular health.

Purpose of the Study:

• To review currently available lipid-lowering agents.
• To discuss recent advancements in lipid-lowering regimens.
• To highlight the importance of achieving low LDL-C levels (<30 mg/dL) in high-risk patients.

Main Methods:

• Review of current lipid-lowering agents including statins, ezetimibe, PCSK9 inhibitors, Inclisiran (siRNA), and bempedoic acid.
• Discussion of recent changes in therapeutic strategies, such as early combination therapy.
• Focus on practical aspects of lipid management.

Main Results:

• The relative risk reduction of cardiovascular events is directly proportional to the absolute reduction in LDL-C.
• Various pharmacological agents demonstrate efficacy in lowering LDL-C.
• Newer agents and combination therapies offer improved lipid-lowering potential.

Conclusions:

• Achieving lower LDL-C levels, particularly <30 mg/dL for high-risk individuals, is associated with significant cardiovascular risk reduction.
• The choice of lipid-lowering agent and therapeutic strategy should be individualized based on patient risk.
• Continued advancements in lipid-lowering therapies are essential for managing atherosclerotic cardiovascular disease.